---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-011724"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2022-02-04T23:59:59+00:00"
generated_at: "2026-06-27T11:04:25.141218+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience Q1 FY2022: revenue $42M (+49% YoY), orders up 48%, raises FY guidance

## Summary
- Revenue of $42.0M (up 49% from $28.2M YoY); orders of $49.6M (up 48% from $33.6M).
- Net loss $45.6M ($0.91 per share) vs $32.9M ($0.72 per share) in prior year.
- Cash, cash equivalents and investments $408.7M as of Dec 31, 2021; shipped to ~1,800 customers.
- Raised fiscal 2022 revenue guidance; specific numbers not provided in the press release excerpt.

## SEC filing metadata
- accession: 0001104659-22-011724
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2022-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000110465922011724/0001104659-22-011724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000110465922011724/tm224740d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-011724
- JSON: https://secwatch.observer/filing/0001104659-22-011724.json
- Plain text: https://secwatch.observer/filing/0001104659-22-011724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.